Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Cuts 25 Percent of Workforce

SAN FRANCISCO, Jan. 22 - Lynx Therapeutics said today that it was laying off 25 percent of its staff.

 

The cutting of 30 people, primarily research and development staff based in Heidelberg, Germany, and workers in the proteomics group in California, brings the total company headcount to 90 people, according to Lynx.

 

In April Lynx laid off 44 employees.

 

This round of layoffs marks the discontinuation of the company's proteomics development efforts, including investment in its Protein Profiler, Lynx CEO Kevin Corcoran said in a statement.

 

"Our business strategy will focus on MPSS, our product that currently generates revenues for us primarily through genomics discovery services for our customers," said Corcoran.

 

Last week, Lynx received additional notice by Nasdaq that the company was in danger of being delisted from the stock exchange.

 

 

 

 

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.